Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Comment by LtGhoston Mar 05, 2020 11:53am

116 Views

Post# 30770702

RE:RE:RE:HALTED!

Mixed feeling now after the NR...

I felt very good on holding Kly until this morning NR, few points make me confused...

1) are we aquiring stero or the other way around? If our price remaining the same or less at closing, the current kly shareholders will only have ~30% of the company and Stero becomes the major shareholder.

2) Chairman and CEO will become Mr David Bassa, the CEO of stero.

3) we are all waiting for the licensing deal, and suddenly the stero acquisition, to me, I feel the potential is diluted and shared with the stero shareholders.

4) reason of halted: pending company contact.

i see the potential of kly, and hope everything turn out ok. Too late to back out now, double or nothing, GLTA

Bullboard Posts

Canadian artificial intelligence ETFs